Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953044 | 0.96 | ALOX5 (0.48) | ALOX5CALM1PPARAF2RL1ALDH1A1 | |
| SCHEMBL2622478 | 0.84 | ARG1 (0.47) | PPARAIGF1RALOX15ARG1ARG2 | |
| SCHEMBL14818917 | 0.82 | ARG1 (0.49) | IGF1RALOX15LTB4RARG1ARG2 | |
| SCHEMBL2632241 | 0.82 | S1PR1 (0.61) | ALDH1A1SPHK2 | |
| SCHEMBL13953043 | 0.80 | GLA (0.48) | ALOX5CALM1F2RL1ALDH1A1SPHK2 | |
| SCHEMBL6256659 | 0.80 | S1PR1 (0.60) | CALM1IGF1RALOX15SPHK2 | |
| SCHEMBL13932769 | 0.78 | S1PR1 (0.62) | ALDH1A1 | |
| SCHEMBL13953378 | 0.77 | ALDH1A1 (0.43) | ALOX15F2RL1ALDH1A1 | |
| SCHEMBL7614064 | 0.77 | ALOX5 (0.49) | ALOX5CALM1IGF1RALOX15 | |
| SCHEMBL22033168 | 0.77 | F2RL1 (0.46) | PPARAF2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008083280-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | TRANSITION THERAPEUTICS INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7189748-B2 | Compounds and methods for treating insulin resistance and cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | CPT1A, CPT1B, PNLIP | ALOX5 366/4885CALM1 1656/4885PPARA 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.